Novel therapeutics categorized by pharmacologic class and target of interaction.
| Target and Pharmacologic Class . | Agent . |
|---|---|
| Survival signals | |
| Anti-Angiogenic | thalidomide (Thalomid™) CC5013 (lenalidomide, RevliMid™) bevacizumab (Avastin™) arsenic trioxide (Trisenox™) |
| Receptor Tyrosine Kinase Inhibitors | PTK787 imatinib mesylate (Gleevec™) |
| Protein Kinase C Inhibitor | PKC412 |
| p38αMAPK Inhibitor | SC10469 |
| Matrix Metalloprotease Inhibitor | AG3340 (Prinomastat™) |
| Farnesyl transferase Inhibitors | R115777 (tipifarnib, Zarnestra™) SCH66336 (lonafarnib, Sarasar™) |
| Pharmacologic Differentiators | TLK199 (Telintra™) |
| Target and Pharmacologic Class . | Agent . |
|---|---|
| Survival signals | |
| Anti-Angiogenic | thalidomide (Thalomid™) CC5013 (lenalidomide, RevliMid™) bevacizumab (Avastin™) arsenic trioxide (Trisenox™) |
| Receptor Tyrosine Kinase Inhibitors | PTK787 imatinib mesylate (Gleevec™) |
| Protein Kinase C Inhibitor | PKC412 |
| p38αMAPK Inhibitor | SC10469 |
| Matrix Metalloprotease Inhibitor | AG3340 (Prinomastat™) |
| Farnesyl transferase Inhibitors | R115777 (tipifarnib, Zarnestra™) SCH66336 (lonafarnib, Sarasar™) |
| Pharmacologic Differentiators | TLK199 (Telintra™) |